MASCT by Hengrui Yuanzheng Biotechnology for Metastatic Colorectal Cancer: Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Metastatic Colorectal Cancer.

High-precision X-rays uncover the mechanics of neck pain

Learning new languages, sending emails, attending a virtual class, or speaking to loved ones halfway around the world are just some of the tasks accomplished

September 5, 2024

Clinical Challenges: Immunotherapy’s Potential in the Neoadjuvant Setting

The impact of immunotherapy, specifically immune checkpoint inhibitors, in advanced and metastatic cancer quickly led to interest in using the therapy in earlier-stage disease. Most

October 7, 2023

New study links childhood BMI trajectories to adult lung health

Researchers examine interactions between early life body mass index values and later life lung function.

November 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.